Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Anna Castleton, Michelle Lannon, Ned Atiyah et al. Nov 03, 2025 pp. 1565-1565 10.1182/blood-2025-1565

Abstract Background The UK Adult ALL CAR-T panel - established May 2023 - promotes equity of access and consistent eligibility assessment fo...

Optimal dosing of vobramitamab duocarmazine, a CD276 (B7-H3) antibody-drug conjugate, leads to durable eradication of Acute Myeloid Leukemia in preclinical xenograft models

Danielle Kirkey, Melia Blankenfeld, Deryk Loo et al. Nov 03, 2025 pp. 5064-5064 10.1182/blood-2025-5064

Abstract CD276 (B7-H3) is an immune checkpoint inhibitor aberrantly expressed in a majority of solid tumors and hematologic malignancies, wi...

α-synuclein aggregates inhibit reticulocyte maturation

Yijin Chen, Peizheng Yang, Yanjuan Liu et al. Nov 03, 2025 pp. 1117-1117 10.1182/blood-2025-1117

Abstract Anemia is highly associated with Parkinson's disease (PD), yet the underlying mechanisms linking PD to erythropoiesis remain poorly...

Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial

Hong-Hong Yan, Xin Huang, Ping Wu et al. Nov 03, 2025 pp. 8252-8252 10.1182/blood-2025-8252

Abstract Background Induction therapy is the first critical step in the overall treatment of Acute myeloid leukemia (AML). The “3+7” regimen...

A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Hanzhen Zhang, Xutao Guo, Qi Wei et al. Nov 03, 2025 pp. 5478-5478 10.1182/blood-2025-5478

Abstract Our previous pilot study demonstrated that the combination of sintilimab, rituximab, and lenalidomide (sR2) is effective and well t...

Cdc42 controls spatial organization of autophagy in hematopoietic stem cells

Cuiqing Fan, Ryan Jorgensen, Zhaowei Tu et al. Nov 03, 2025 pp. 3152-3152 10.1182/blood-2025-3152

Abstract Autophagy is a fundamental cellular process essential for hematopoietic stem cell (HSC) maintenance by removing damaged organelles/...

The infection spectrum in newly diagnosed Acute Myeloid Leukemia patients treated with venetoclax-based or conventional chemotherapy: A real-world retrospective study

Guilin Ren, Li Wang Nov 03, 2025 pp. 1610-1610 10.1182/blood-2025-1610

Abstract To better characterize the infection risk profile associated with venetoclax-based regimens in AML, we conducted a retrospective an...

Immune reconstitution and infectious complications following CAR-T cell therapy

Pedro Rodrigues Santos, Daniela Maia, Fernanda Seganfredo et al. Nov 03, 2025 pp. 4149-4149 10.1182/blood-2025-4149

Abstract Background: CAR-T therapies have dramatically improved outcomes of relapsed/refractory B cell lymphoma patients (pts). However, thi...

HBB-mafk axis drives lipid metabolism reprogramming and tumor progression in diffuse large B-cell lymphoma

Yunxia Zhang, Haohao Lei, Xutao Guo Nov 03, 2025 pp. 6777-6777 10.1182/blood-2025-6777

Abstract Background: Diffuse large B cell lymphoma (DLBCL), a heterogeneous disease, constitutes the most common subtype of non-Hodgkin lymp...

Biphasic effects of cyclophosphamide on l-asparaginase hypersensitivity and resistance in mice

Ai Nogami-Hara, Akinobu Hatae, Mitsunobu Mio Nov 03, 2025 pp. 1531-1531 10.1182/blood-2025-1531

Abstract Background: L-Asparaginase (ASNase), a crucial drug for childhood acute lymphoblastic leukemia (ALL) treatment, frequently causes a...

A platelet-activating, HPA-1a-specific maternal alloantibody identifies a pathogenic subpopulation with the potential to exacerbate fetal/neonatal alloimmune thrombocytopenia

Huiying Zhi, Cathy Paddock, Gestur Vidarsson et al. Nov 03, 2025 pp. 4794-4794 10.1182/blood-2025-4794

Abstract Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a potentially life-threatening condition caused by maternal alloantibodies di...

Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data.

Jananee Muralidharan, William Pike, Saurabh Gombar et al. Nov 03, 2025 pp. 4341-4341 10.1182/blood-2025-4341

Abstract Background Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare (3.81 per 100K), treatable clonal hematopoietic...

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Ducourneau Benoit, Arnaud Pages, Stéphanie Struski et al. Nov 03, 2025 pp. 7002-7002 10.1182/blood-2025-7002

Abstract Acute myeloid leukemia (AML) harboring NUP98 rearrangements (NUP98r) is recognized as a distinct entity in the 2022 WHO classificat...

A mammalian protein-based coacervate platform enables scalable engineering for CAR-T therapy

Peipei Zhu, Manman Lu, Qing Zhang et al. Nov 03, 2025 pp. 7622-7622 10.1182/blood-2025-7622

Abstract The advancement of CAR-T cell therapies has reshaped treatment strategies for hematologic malignancies, yet the production of genet...

Total effect of gestational hypertension on neonatal iron deficiency in very-preterm infants.

Hudson Barr, Victoria Hamilton, Nathan Mckenzie et al. Nov 03, 2025 pp. 4688-4688 10.1182/blood-2025-4688

Abstract Background: Gestational hypertension (GH) is a major risk factor for adverse maternal and perinatal morbidity and outcomes, includi...

Monitoring MRD and clinical utility of DNMT3A R882 in AML by multiplex droplet digital PCR

Xinhai Deng, Keyi Chen, Yixuan Li et al. Nov 03, 2025 pp. 7867-7867 10.1182/blood-2025-7867

Abstract ObjectiveCurrent clinical detection of the DNMT3A R882 variant is usually by NGS and sanger sequencing, but the traditional methods...

Noninvasive detection and monitoring of multiple myeloma by urinary surface-enhanced raman spectroscopy and machine learning

Xinran Zhu, Lintao Bi, Di Zhou et al. Nov 03, 2025 pp. 7876-7876 10.1182/blood-2025-7876

Abstract Abstract Background: Multiple myeloma (MM) is the second most common hematologic malignancy, characterized by high relapse rates an...

Dysfunction of the neurovascular unit (NVU) presents a novel indicator for CNS injury after allogeneic hematopoietic stem cell transplantation

Vasantharaja Raguraman, Ishan Pathak, Shanid Mohiyuddin et al. Nov 03, 2025 pp. 4093-4093 10.1182/blood-2025-4093

Abstract Introduction: Graft-versus-host-disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (HS...

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Stephen Smith, Francesc Bosch Albareda, Danielle Wallace et al. Nov 03, 2025 pp. 3594-3594 10.1182/blood-2025-3594

Abstract Background Single-agent R is a common 1st-line therapy for patients (pts) with FL, especially those with low-tumor burden advanced s...

Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts

Mirco Friedrich, Julie Pham, Jiakun Tian et al. Nov 03, 2025 pp. 380-380 10.1182/blood-2025-380

Abstract Introduction: Aging impairs immune function and leads to increased vulnerability to infection, malignancy, and vaccine failure.Immu...

Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia

Zhangliang Cheng, Kohei Kume, Ruoyi Shi et al. Nov 03, 2025 pp. 1485-1485 10.1182/blood-2025-1485

Abstract Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with rare, phenotypically...

Treatment strategies and outcomes in pediatric patients with immune thrombocytopenia (ITP) undergoing surgical procedures: A multicenter study

Matthew Ross, Lia Phillips, Kristyn Pierce et al. Nov 03, 2025 pp. 3046-3046 10.1182/blood-2025-3046

Abstract Introduction: Children with immune thrombocytopenia (ITP) may have an increased risk of perioperative bleeding. However, current IT...

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Alexander Lesokhin, Ruben Niesvizky, Bertrand Arnulf et al. Nov 03, 2025 pp. 2269-2269 10.1182/blood-2025-2269

Abstract Background Elranatamab (ELRA) is a B-cell maturation antigen (BCMA)-CD3 bispecific antibody indicated for the treatment of adult pa...

Synergistic effects of ASXL1 and BCOR on hematopoiesis and MDS/AML progression

Rongtao Xue, Yuting Qin, Ya Zhou et al. Nov 03, 2025 pp. 1462-1462 10.1182/blood-2025-1462

Abstract Background: Myelodysplastic syndromes (MDS) and MDS-transformed acute myeloid leukemia (AML) are hematologic malignancies that pose...

Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (<70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study

Fayaz Khan, Renu Bhargavi Boyapati, Zuhair Alam Nov 03, 2025 pp. 2212-2212 10.1182/blood-2025-2212

Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapies represent a major advance in the management of relapsed/refractory m...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page